The following is from Children’s Health Defense. Nirsevimab, marketed by Sanofi and AstraZeneca as Beyfortus is a drug developed to protect infants from RSV (respiratory syncytial virus), a virus that can lead to serious respiratory infections. It was fast-tracked for approval by the US […]
(READ) FDA fast-tracked RSV shot linked to infant deaths Read More »
The following is a statement from the Centers for Disease Control and Prevention (CDC). CDC is recommending a new immunization starting this fall to help protect all infants under 8 months and some older babies at increased risk of severe
CDC recommends new RSV vaccine for all infants under 8 months Read More »
The following is from The Vaccine Reaction. On June 8, 2023, the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously (21-0) in favor of AstraZeneca and Sanofi’s new nirsevimab (Beyfortus) monoclonal antibody drug believed to
12 infant deaths reported in clinical trials for FDA-endorsed RSV drug Read More »
The following is from MedPage, which is supported by the pharmaceutical industry. An FDA advisory committee on Thursday gave strong backing to use of a monoclonal antibody against respiratory syncytial virus (RSV) to prevent lower respiratory tract disease (LRTD) in
FDA panel endorses monoclonal antibodies to prevent viral infection in infants Read More »
